companydata.dkcompanydata.dk

Renovaro Biosciences Denmark ApS: Financial statements 2019

CVR: 26027322

Source: annual report 2019, Danish Business Authority

01/07/2018 – 30/06/2019

Renovaro Biosciences Denmark ApS (CVR 26027322) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -1,927,253 and a net result of DKK -6,845,472 compared with DKK -7,012,131 the year before. Equity in the 2019 report amounted to DKK -62,638,645. The company had 1 employee in the financial year.

Gross Profit
DKK -1,927,253
Profit/Loss
DKK -6,845,472
Equity
DKK -62,638,645
Total Assets
DKK 39,372,430
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2019--1.9M-6.8M-62.6M1
2018--4.5M-7M-55.8M-
2016--5M-10.7M-52M2
2015--17.4M-20.4M-41.3M-
2014--8.5M-11.5M-21M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

About Renovaro Biosciences Denmark ApS

Renovaro Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Enochian BioSciences Denmark ApS and DanDrit Biotech ApS. The management consists of David Hershel Weinstein. The company is owned by Lunai Bioworks Inc.. The company has 1 employee (2017). In 2026, the company reported a gross profit of DKK -4,478 and a net result of DKK -1,178,038 compared with DKK -4,629,959 the year before. Equity in the 2026 report amounted to DKK -91,933,986.

Source: annual report 2026, Danish Business Authority